Sumatriptan is a 5-HT1B/D receptor agonist of documented efficacy in reliev
ing migraine and associated symptoms such as nausea and vomiting. In the pa
st decade, several studies reported an important delay of gastric emptying
induced by sumatriptan in healthy humans. The impact of this gastric motor
effect of sumatriptan in migraineurs is difficult to predict: a further del
ay in gastric emptying could be detrimental (i.e. increased nausea and epig
astric symptoms) in patients already having delayed gastric emptying. Howev
er, in patients with functional dyspepsia, sumatriptan is also reported to
improve gastric accommodation to a meal and reduce perception of gastric di
stention, hence relieving epigastric symptoms. Thus, reduced visceral perce
ption could be a mechanism involved in reducing nausea during a migraine at
tack. Paradoxically, sumatriptan is reported both to relieve the nausea of
a migraine attack and to have nausea as a side effect. Although careful ana
lysis of the time of onset of nausea may offer a clue as to the origin of t
his symptom, available data do not support definite conclusions, all the mo
re so because the gastric motor effect of second-generation triptans are st
ill unexplored. Taken together, the available evidence warrants further stu
dies to clarify the following issues: first, the mechanism responsible for
the gastric motor effect of sumatriptan [receptor subtype(s) involved; cent
ral vs peripheral mechanism]; secondly, the effects on gastric motility/vis
ceral sensitivity of second-generation triptans (which are 5-HT1B/D recepto
r agonists) and more recent selective 5-HT1D receptor agonists (proposed as
investigational antimigraine agents with less potential to induce coronary
vasoconstriction through 5-HT1B receptors); finally, the possible use of d
rugs improving gastric accommodation to a meal in the management of those d
yspeptic patients with impaired fundic relaxation/altered visceral sensitiv
ity. (C) 2001 Academic Press.